Med Business World

Your source for healthcare business

Syngene's Q1 Performance Chart 2023
Pharmacy Innovation

Syngene Boosts Biologics Manufacturing Capability Following Impressive Q1 Performance

Syngene International Limited has demonstrated a stellar start to the fiscal year with a 26% YoY surge in both revenues and profit after tax. This strong Q1 performance sets the stage for the company’s strategic expansion plans.

In a significant move, Syngene acquired a biologics manufacturing facility from Stelis Biopharma Ltd. This facility adds a robust 20,000 liters of installed biologics capacity to Syngene’s portfolio, bolstering its position as a leading contract development and manufacturing service provider.

Parallel to its expansion in biologics, Syngene also achieved a milestone with the FDA’s approval of its API manufacturing facility in Mangalore. This validation is a testament to the rigorous quality standards the company maintains across all its operations.

Looking forward, Syngene is committed to bolstering its Research Services division, as evidenced by the acquisition of additional land in Hyderabad. This move is set to facilitate the company’s long-term growth aspirations.



Your email address will not be published. Required fields are marked *